Psoriasis is not just a skin disease it is an immune systemic disorder that, at its root, gives us manifestations on the surface of our skin. Here we describe how MSC therapy may help reset the immune dysregulation that drives psoriatic inflammation, detail what is currently known in terms of evidence and rational for investigating this approach as a supportive strategy to established dermatological care.
For anyone who has lived with psoriasis a skin problem almost never seems to be enough. The itch that disrupts sleep. The plaques that show up ahead of a major event. Unexpected joint pain in psoriatic arthritis. The flares and partial remissions that perpetuate the sense of unplannability. Psoriasis seeps into everyday life in ways topical creams and even oral or injectable drugs sometimes fail to cover. And that is why, for an increasing number of patients the question then as to what else might help has a real and important answer.
One of the more science-backed emerging possibilities being researched is stem cell therapy — specifically, mesenchymal stem cell (MSC) therapy. Not as a treatment, and not as what should replace dermatological care — but rather in terms of an approach that targets the biological underpinnings of immune dysfunction that lies at the heart of this condition.
Figure 1: Stem Cell Therapy for Psoriasis: Immune Balance as a Supportive Approach to Skin Inflammation
What Psoriasis Actually Is
Psoriasis is a chronic autoimmune default of the condition in which our immune system errors by expediting upwards skin cell cycle and crafting new cells much quicker than old ones are shed. This results in the classic accumulation of thick, scaly plaques usually on the elbows, knees, scalp and lower back although it can be seen anywhere.
The immune mechanism that is behind this process is well characterised. Th17 and group 1 innate lymphoid cells, secrete high levels of proinflammatory cytokines like IL-17A, IL-22, IL23 and TNF-α which cause keratinocyte proliferation as well as exacerbate the inflammatory cascade. In the last few years, biologic drugs that target this pathways have revolutionized psoriasis treatment. However, due to their high costs and requirement for chronic administration along with immunosuppressive risks biologics are not equally effective in all patients. It is perfectly logical to look for alternative options that modulate immune dysregulation utilizing a distinct pathway.
How MSC Therapy Fits Into Psoriasis
Unlike the biologics that target a single cytokine pathway, mesenchymal stem cells affect numerous processes simultaneously. Rather, they function as broad-spectrum immune modulators producing a multitude of bioactive molecules that collectively change the dynamic from extended inflammatory activation toward increased regulatory balance.
In psoriasis, the most relevant mechanisms are MSC-mediated expansion of regulatory T cells (Tregs) which can help inhibit aberrant Th17 and TH1 responses that mediate plaque formation. MSCs release prostaglandin E2, IL-10 and TGF-β — three of the better characterized immunosuppressive molecules — while suppressing dendritic cell activation (which represents a crucial early step in psoriatic immune signaling cascade).
More like lowering the volume on a specific alarm rather than silencing it. The aim is not broad-spectrum immunity suppression, but to restore the balance between inflammatory drive and regulatory control that psoriasis perturbs chronically.
What Does The Research Say So Far?
Clinical evidence regarding MSC therapy in psoriasis is still at the nascent stage. Reduction in plaque severity, PASI score and sustained remission were described using case series and small scale clinical observations following MSC infusion. While preclinical studies in mouse models of psoriasiform dermatitis have shown that the transplantation of MSCs resulted in a significant reduction for epidermal thickness and inflammatory infiltrate, which warrants further investigation.
The piece excludes the current absence of solid, sweeping random controlled trial data. The evidence is not yet at the level of standard clinical guidelines, but things are moving in the field there are trials registered ongoing in multiple countries. That context is what patients considering this approach deserve to hear plainly.
The Role of Systemic Inflammation
The systemic inflammatory burden associated with psoriasis is one area that MSC therapy may be ideally suited to target. Moderate-to-severe psoriasis subjects have a greatly increased risk of cardiovascular disease, metabolic syndrome and inflammatory arthritis risks related not to the skin plaques themselves but instead limited by the immune dysregulation which produces them.
If MSC therapy can meaningfully decrease systemic inflammatory markers as early data suggest it may do so in some cases, then its potential advantages would be all the more pronounced. Outcomes that make a meaningful difference to patients living with the full spectrum of this debilitating disease include reduced cardiovascular risk, less joint discomfort in psoriatic arthritis and improved control of inflammation overall.
A Grounded Perspective for Patients
Management of psoriasis is rarely one size fits all. Patients who do best are those in collaboration with a dermatologist over time, who identify and manage known triggers, use evidence-based treatments consistently, but remain open to adjunct options that an appropriately qualified specialist considers appropriate to their individual profile.
Stem cell therapy for psoriasis is still firmly in the investigational category. The underlying biological rationale is plausible, the preliminary signals appear cautiously favorable in limited human studies and the safety profile of MSC-based strategies has been reasonably favorable based on available literature reports. However, it is not presently a first-line choice and the moment any center promotes that it’s an absolute answer should be met with instant skepticism.
At its most honest it illustrates a biological rationalization to what is really an attempt at immunosuppression that typical therapies are sometimes capable of accomplishing but rarely purging entirely. For the patient who has exhausted conventional options or for those who wish to adopt a more root-cause oriented method alongside their current treatment it is definitely worth having this talk, with the right specialist and proper expectations.
References
Boehncke, W.H., & Schön, M.P. (2015). Psoriasis. The Lancet, 386(9997), 983–994.
Crop, M.J., Baan, C.C., Korevaar, S.S., et al. (2010). Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clinical & Experimental Immunology, 162(3), 474–486.
Gao, F., Chiu, S.M., Motan, D.A.L., et al. (2016). Mesenchymal stem cells and immunomodulation: Current status and future prospects. Cell Death & Disease, 7(1), e2062.
Griffiths, C.E.M., Armstrong, A.W., Gudjonsson, J.E., & Barker, J.N.W.N. (2021). Psoriasis. The Lancet, 397(10281), 1301–1315.
Shi, Y., Su, J., Roberts, A.I., Shou, P., Rabson, A.B., & Ren, G. (2012). How mesenchymal stem cells interact with tissue immune responses. Trends in Immunology, 33(3), 136–143.